What is RayzeBio?
RayzeBio is a pioneering biotechnology enterprise dedicated to transforming cancer care through the application of targeted radioisotopes. By leveraging clinically validated solid tumor targets, the company develops novel drug conjugates designed to deliver potent therapeutic agents, such as Actinium-225, directly to malignant cells. This precision-medicine approach aims to improve patient outcomes by minimizing off-target toxicity while maximizing therapeutic efficacy. As a key player in the radiopharmaceutical sector, RayzeBio occupies a critical niche at the intersection of molecular biology and advanced oncology, supported by a sophisticated syndicate of healthcare-focused investors.
How much funding has RayzeBio raised?
RayzeBio has raised a total of $418M across 4 funding rounds:
Series A
$45M
Series B
$105M
Series C
$108M
Series D
$160M
Series A (2020): $45M with participation from venBio Partners LLC, Samsara Bio-Pharma, and Versant Ventures GmbH
Series B (2020): $105M led by LifeSci Venture Partners, Redmile Group, Alexandria Venture Investments, Cormorant Asset Management, Viking Global Investors, Logos Capital, Venrock Healthcare Capital Partners, and OrbiMed
Series C (2021): $108M supported by Viking Global Investors, Versant Ventures, Perceptive Advisors, HealthQuest Capital, Vivo Capital, venBio Partners, LifeSci Venture Partners, OrbiMed, Samsara BioCapital, TCG X, Redmile Group, Logos Capital, Alexandria Venture Investments, Deerfield, and Cormorant Asset Management
Series D (2022): $160M featuring Wellington Management, Viking Global Investors, Ally Bridge Group, and Sands Capital
Key Investors in RayzeBio
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries and geographies.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains, managing capital across biopharmaceuticals and medical devices.
Versant Ventures
Versant Ventures partners with exceptional entrepreneurs to build and fund innovative biotechnology companies globally, leveraging a strong track record of over 50 IPOs and M&A transactions.
What's next for RayzeBio?
With the recent influx of capital, RayzeBio is well-positioned to advance its lead candidates through critical clinical milestones. The strategic focus will likely shift toward expanding its manufacturing capabilities and deepening its research into next-generation alpha-emitters. Given the current lifecycle stage, the company is expected to prioritize data generation and regulatory engagement to validate its platform's clinical utility. The ongoing support from institutional heavyweights suggests a clear path toward potential commercialization or strategic partnership opportunities, ensuring the firm remains at the forefront of the rapidly evolving radiopharmaceutical industry.
See full RayzeBio company page
